Ocular Therapeutix (OCUL) Misses Q4 EPS by 7c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.52), $0.07 worse than the analyst estimate of ($0.45).

• PDUFA Target Action Date of July 19, 2017 for the DEXTENZA™ NDA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance
• Darden Restaurants (DRI) Tops Q4 EPS by 3c, Misses on Revenue; Offers FY27 Guidance